Zimmer Biomet Holdings (ZBH) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98956P1021

Hip, Knee, Sports Medicine, Biologics, Trauma, Orthopedic, Surgical

Zimmer Biomet Holdings Inc. is a global medical technology company that designs, manufactures, and markets a wide range of innovative products to improve the lives of people suffering from musculoskeletal disorders or injuries. The company's portfolio includes orthopedic reconstructive products, such as knee and hip implants, as well as sports medicine and biologics products that help to repair and heal damaged tissues.

The company's S.E.T. products, which include sports medicine, biologics, foot and ankle, extremities, and trauma products, are designed to address various orthopedic conditions and injuries. Additionally, Zimmer Biomet offers craniomaxillofacial and thoracic products, including face and skull reconstruction products, as well as products that help to fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Zimmer Biomet's product portfolio also includes robotic, surgical, and bone cement products that are used in various orthopedic procedures. The company's products and solutions are used to treat a wide range of musculoskeletal disorders and injuries, including osteoarthritis, bone fractures, and soft tissue injuries. By providing innovative products and solutions, Zimmer Biomet aims to improve patient outcomes and enhance the quality of life for people around the world.

Zimmer Biomet serves a diverse range of customers, including orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists. The company has a strong global presence, with a network of agents, healthcare purchasing organizations, and buying groups that help to distribute its products to customers worldwide.

Zimmer Biomet has a rich history, dating back to 1927, and is headquartered in Warsaw, Indiana. The company has undergone significant transformations over the years, including a name change to Zimmer Biomet Holdings Inc. in June 2015. Today, Zimmer Biomet is a leading global medical technology company that is committed to improving the lives of people through innovative products and solutions.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Zimmer Biomet Holdings (ZBH) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Zimmer Biomet Holdings (ZBH) - Stock & Dividends

ZBH Stock Overview

Market Cap in USD 23,267m
Sector Healthcare
Industry Medical Devices
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 2001-07-25

ZBH Stock Ratings

Growth 5y -9.64
Fundamental 21.5
Dividend 5.25
Rel. Performance vs Sector -3.92
Analysts 3.43/5
Fair Price Momentum 96.72 USD
Fair Price DCF 125.58 USD

ZBH Dividends

Yield 12m 0.90%
Yield on Cost 5y 0.86%
Dividends CAGR 5y 0.61%
Payout Consistency 98.4%

ZBH Growth Ratios

Growth 12m -24.92%
Growth Correlation 12m -6%
Growth Correlation 3m -76%
CAGR 5y -0.87%
CAGR/Mean DD 5y -0.04
Sharpe Ratio 12m -1.45
Alpha vs SP500 12m -53.21
Beta vs SP500 5y weekly 1.08
ValueRay RSI 12.13
Volatility GJR Garch 1y 23.38%
Price / SMA 50 -9.62%
Price / SMA 200 -9.49%
Current Volume 1579.4k
Average Volume 20d 1523.3k

External Links for ZBH Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of ZBH stocks?
As of June 18, 2024, the stock is trading at USD 107.03 with a total of 1,579,388 shares traded.
Over the past week, the price has changed by -5.18%, over one month by -10.94%, over three months by -14.87% and over the past year by -25.15%.
What are the forecast for ZBH stock price target?
According to ValueRays Forecast Model, ZBH Zimmer Biomet Holdings will be worth about 106.6 in June 2025. The stock is currently trading at 107.03. This means that the stock has a potential downside of -0.41%.
Issuer Forecast Upside
Wallstreet Target Price 136.4 27.5
Analysts Target Price 143.8 34.3
ValueRay Target Price 106.6 -0.41